Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2012
12/13/2012CA2833771A1 Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
12/13/2012CA2833507A1 Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
12/12/2012EP2533050A1 Treatment options for Fabry disease
12/12/2012EP2533047A1 CCR4 as therapeutic target for cancer.
12/12/2012EP2532686A1 Process methods for fucoidan purification from seaweed extracts
12/12/2012EP2532674A1 Long-acting polypeptides and methods of producing and administering same
12/12/2012EP2532671A1 Novel synthetic glycolipid and use thereof
12/12/2012EP2532668A1 Optically active 2-hydroxy tetrahydrothienopyridine derivatives, preparation method and use in manufacture of medicament thereof
12/12/2012EP2532667A1 Deazapurines useful as inhibitors of janus kinases
12/12/2012EP2532666A1 Pharmaceutically acceptable salts of pyrrolo-nitrogenous heterocyclic derivatives, preparation method and medical use thereof
12/12/2012EP2532665A1 Benzimidazole derivatives and pharmaceutical compositions and uses thereof
12/12/2012EP2532664A1 Substituted indolo [2,3-a] quinolizines in the treatment of cancer
12/12/2012EP2532659A1 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
12/12/2012EP2532658A1 Therapeutic agent for cerebral infarction
12/12/2012EP2532657A2 Compounds and methods of use
12/12/2012EP2532656A1 Gpr119 agonist
12/12/2012EP2532654A1 Crystalline forms of febuxostat
12/12/2012EP2532652A1 Therapeutic agent for hepatitis c
12/12/2012EP2532651A1 Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide hydrochloride and its free base as well as the pharmaceutical compositions containing them
12/12/2012EP2532650A2 Modulators of ATP-binding cassette transporters
12/12/2012EP2532649A1 Amino lipids, their synthesis and uses thereof
12/12/2012EP2532648A1 Locally active "soft" antiandrogens
12/12/2012EP2532647A1 New co-crystals of agomelatin
12/12/2012EP2532643A1 IRE-1A Inhibitors
12/12/2012EP2532390A2 Pharmaceutical composition for obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
12/12/2012EP2532389A2 Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
12/12/2012EP2532388A2 Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
12/12/2012EP2532352A1 Stabilized Sulforaphane
12/12/2012EP2532351A1 Agent for improving motility function
12/12/2012EP2532350A1 Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome
12/12/2012EP2532254A1 Method for treatment of lacto-n-biose-containing solution
12/12/2012EP2532251A1 Functional food and pharmaceutical compositions for anti-obesity comprising capsanthin and its fatty acylester derivatives having anti-adipogenic activity
12/12/2012EP2532242A1 Use of bispyridiniumalkanes for killing spores
12/12/2012EP2532241A1 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
12/12/2012EP2532235A1 Inhibitors of bruton's tyrosine kinase
12/12/2012EP2532234A1 Inhibitors of bruton's tyrosine kinase
12/12/2012EP2531859A2 Compositions and methods of modulating receptor protein tyrosine phosphatases
12/12/2012EP2531604A2 Compositions and methods for enhanced parvovirus transduction
12/12/2012EP2531598A1 Whsc1 and whsc1l1 for target genes of cancer therapy and diagnosis
12/12/2012EP2531531A1 Branched soluble glucose polymers for peritoneal dialysis
12/12/2012EP2531516A2 Pregnane compounds condensed in position 16,17 with a pyrolidine ring with glucocorticoid activity
12/12/2012EP2531511A1 Fatty acid amide hydrolase inhibitors
12/12/2012EP2531510A1 Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
12/12/2012EP2531509A1 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
12/12/2012EP2531508A1 Pyrrolo [ 2, 3 - d]pyrimidine urea compounds as jak inhibitors
12/12/2012EP2531507A1 Crystalline forms of (s)-1-(4-(5-cyclopropyl-1h-pyrazol-3- ylamino)pyrrolo [1,2-f][1,2,4]triazin-2-yl)-n-(6-fluoropyridin- 3-yl)-2-methylpyrrolidine-2-carboxamide
12/12/2012EP2531506A1 S piroindoline compounds for use as anthelminthi cs
12/12/2012EP2531503A1 Gamma secretase modulaters
12/12/2012EP2531502A1 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
12/12/2012EP2531501A1 Apoptosis signal-regulating kinase 1 inhibitors
12/12/2012EP2531500A1 Hetaryl-[1,8]naphthyridine derivatives
12/12/2012EP2531498A1 Compounds and compositions as protein kinase inhibitors
12/12/2012EP2531492A1 1,2,4-triazine-4-amine derivatives
12/12/2012EP2531490A1 Cyclohexyl amide derivatives as crf receptor antagonists
12/12/2012EP2531488A2 Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors
12/12/2012EP2531487A1 Aryl benzylamine compounds
12/12/2012EP2531485A2 Highly selective 5-ht(2c) receptor agonists having antagonist activity at the 5-ht(2b) receptor
12/12/2012EP2531261A2 Methods for diagnosis and treatment of non-insulin dependent diabetes mellitus
12/12/2012EP2531223A2 Novel methods and utilities
12/12/2012EP2531202A2 Use of oral heparin preparations to treat urinary tract diseases and conditions
12/12/2012EP2531201A1 Synthesis of dgjnac from d-glucuronolactone and use to inhibit alpha-n-acetylgalactosaminidases
12/12/2012EP2531200A1 Crystallization method and bioavailability
12/12/2012EP2531199A2 Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor
12/12/2012EP2531198A1 Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
12/12/2012EP2531197A1 Solid state forms of macrocyclic kinase inhibitors
12/12/2012EP2531196A2 Pterostilbene cocrystals
12/12/2012EP2531195A1 Use of theobromine for lowering central blood pressure
12/12/2012EP2531194A1 Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
12/12/2012EP2531193A1 Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same
12/12/2012EP2531192A1 Treatment of chlamydiaceae infections by means of beta-lactams
12/12/2012EP2531191A1 Sigma ligands for use in the prevention and/or treatment of postoperative pain
12/12/2012EP2531190A1 Tetrahydro-pyran derivatives against neurological illnesses
12/12/2012EP2531189A1 Combination composition, comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency
12/12/2012EP2531188A1 Treatment of respiratory disorders
12/12/2012EP2531187A1 sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS
12/12/2012EP2531186A2 Treatment skin disorders
12/12/2012EP2531185A2 Combination therapy for treating cancer comprising an igf-1r inhibitor and an hdac inhibitor
12/12/2012EP2531184A1 Docosahexaenoic acid ethyl esters and/or its derivatives for prevention and/or treatment of age-related macular degeneration
12/12/2012EP2531183A2 Antimicrobial compounds
12/12/2012EP2531182A1 Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
12/12/2012EP2531181A1 Extended release formulations of rasagiline and uses thereof
12/12/2012EP2531180A2 Oral complex composition comprising pseudoephedrine and levocetirizine
12/12/2012EP2531179A1 Pharmaceutical composition comprising n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
12/12/2012EP2531177A1 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
12/12/2012EP2531175A2 Liposomes comprising amphipathic drugs and method for their preparation
12/12/2012EP2531173A2 Taxane-and taxoid-protein compositions
12/12/2012EP2531172A1 Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
12/12/2012EP2531034A1 Aqueous-miscible or aqueous-dispersible, voc-free biocidal compositions for the enhanced inhibition of gram-negative bacterial strains, and method of preparing the same
12/12/2012EP2531033A1 Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
12/12/2012EP2531032A1 Materials and method for inhibiting replication protein a and uses thereof
12/12/2012EP2531029A1 Selective androgen receptor modulators
12/12/2012EP2531028A1 Tocotrienol esters
12/12/2012EP2531027A1 Antiviral therapy
12/12/2012EP2531026A1 Polysaccharide based antimicrobial formulations
12/12/2012DE202011109558U1 Zusammensetzung für die topische Anwendung bei entzündlichen Erkrankungen der Haut und/oder Schleimhaut Composition for topical use in inflammatory diseases of the skin and / or mucosa
12/12/2012CN102822673A Method for preparing polybiotinylated compounds
12/12/2012CN102822342A Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
12/12/2012CN102822200A Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
12/12/2012CN102822190A Mammalian metabolites of steroids
12/12/2012CN102822188A Adenosine compounds and their use thereof
1 ... 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 ... 7860